9 Reasons Hypermobile Ehlers-Danlos Syndrome and Perimenopause Create a Uniquely Difficult and Dangerous Combination
So many women in the hEDS community describe perimenopause as the moment everything fell apart at once — joints they had managed for years suddenly subluxing daily, heart rate spiraling, and a fatigue that made their pre-perimenopause baseline feel like a distant luxury. If that sounds familiar, this is not in your head and it is not a coincidence. The estrogen connection is real, it is documented, and knowing about it changes everything about how you advocate for yourself.
Learn more about Rose →Estrogen Directly Regulates Collagen Synthesis — and hEDS Collagen Is Already Compromised
Estrogen receptors are found on fibroblasts, the cells responsible for producing and maintaining collagen throughout the body. In healthy connective tissue, estrogen upregulates collagen type I synthesis and supports the cross-linking that gives tissue tensile strength. In hEDS, where collagen structure is already genetically altered and functionally fragile, the withdrawal of this estrogenic support during perimenopause accelerates laxity in ways that go well beyond what most women without a connective tissue disorder will ever experience.
Joint Instability and Subluxations Worsen as Estrogen Falls
Research in both sports medicine and rheumatology has consistently shown that ligament laxity fluctuates with estrogen levels — female athletes are well-documented to have higher ACL injury rates in the low-estrogen phase of their menstrual cycle. For women with hEDS, who already have structurally lax ligaments, the sustained low-estrogen environment of perimenopause can push joints that were previously manageable into a new pattern of frequent subluxations and dislocations. This is not gradual adaptation; many women report a step-change in joint behavior within months of hormonal decline beginning.
POTS Symptoms Intensify Because Estrogen Supports Vascular Tone
Postural Orthostatic Tachycardia Syndrome affects an estimated 70–80% of people with hEDS, driven by the same connective tissue laxity that allows blood vessel walls to distend abnormally and pool blood in the lower body. Estrogen plays a separate but compounding role here: it supports vascular smooth muscle tone and influences baroreceptor sensitivity, both of which help regulate blood pressure on standing. As estrogen declines in perimenopause, women with hEDS-associated POTS often see their heart rate spikes, pre-syncope episodes, and exercise intolerance worsen significantly beyond their prior baseline.
Mast Cell Activation Syndrome Flares Are Triggered by Hormonal Flux
Mast Cell Activation Syndrome co-occurs with hEDS at rates far above the general population, and mast cells are exquisitely sensitive to hormonal signals — estrogen can both prime mast cells for degranulation and, at stable physiological levels, provide some regulatory suppression of their activity. The volatile estrogen fluctuations of perimenopause, where levels spike unpredictably before declining, can trigger waves of mast cell activation that manifest as flushing, hives, gastrointestinal cramping, anaphylactoid reactions, and neurological symptoms. Women managing previously stable MCAS often find perimenopause triggers their most severe and difficult-to-control flare period.
Central Sensitization and Pain Amplification Deepen as Estrogen Withdraws
Estrogen modulates pain processing at multiple points in the central nervous system, including influencing serotonin, dopamine, and endorphin pathways that act as natural analgesic brakes. hEDS is already strongly associated with central sensitization — a state where the nervous system is chronically upregulated and processes ordinary sensory input as painful. The loss of estrogen's pain-dampening influence during perimenopause effectively turns up the volume on a system that was already dialed too high, contributing to widespread pain, allodynia, and a dramatically lowered pain threshold that can feel bewildering even to women experienced with managing chronic hEDS pain.
Pelvic Floor Dysfunction Becomes Significantly More Complex
The pelvic floor in hEDS is connective tissue, and it is subject to the same laxity and instability that affects every other joint and fascia in the body. Estrogen maintains the thickness, elasticity, and neuromuscular coordination of pelvic floor tissue, and its decline accelerates genitourinary atrophy, pelvic organ prolapse risk, and bladder instability — all of which are already elevated risks in hEDS. The combination creates a clinical picture that standard pelvic floor protocols are often ill-equipped to address, because the tissue does not respond in predictable ways when both hormonal and structural integrity are simultaneously compromised.
Autonomic Nervous System Dysregulation Compounds From Two Directions
Dysautonomia — the broad dysfunction of the autonomic nervous system that underlies POTS and many other hEDS-related symptoms — is partly mediated by the same connective tissue laxity that affects blood vessel walls and baroreceptor function. Estrogen independently supports autonomic balance by influencing the parasympathetic nervous system and modulating sympathetic tone. When estrogen drops, women with hEDS are losing autonomic regulation from both angles simultaneously: their structural connective tissue support is worsening and their hormonal neurological regulation is withdrawing, leaving the autonomic system with far fewer stabilizing inputs.
Brain Fog in hEDS Becomes Severe Enough to Mimic Neurological Disease
Cognitive symptoms — difficulty retrieving words, poor working memory, inability to concentrate — are common in both perimenopause and hEDS independently, with hEDS-related brain fog linked to cerebral blood flow dysregulation secondary to dysautonomia. In perimenopause, declining estrogen reduces cerebral glucose metabolism and disrupts the glymphatic system's overnight brain-clearing function. Women with hEDS entering perimenopause frequently report that their cognitive symptoms cross a threshold into territory that genuinely impairs their ability to work, drive, and communicate — and because both conditions are under-recognized, they are often told this is anxiety or depression rather than a physiological cascade.
Standard Menopause Care and Standard hEDS Care Both Fail This Population
Most menopause specialists are not trained in connective tissue disorders, and most rheumatologists and geneticists managing hEDS are not focused on hormonal transitions — leaving women with hEDS in perimenopause navigating a gap between two specialties that rarely communicate. Hormone replacement therapy, which has strong evidence for reducing connective-tissue-related symptom burden and supporting vascular tone, is underutilized in this population partly because clinicians do not connect hormonal decline to the worsening of hEDS symptoms. Advocating for HRT evaluation as a legitimate part of hEDS management during perimenopause is one of the most important and underused strategies available to this group.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.